GLP-1 drugs are driving up healthcare costs

he rapid adoption of GLP-1 drugs as obesity therapies has led to a zeitgeist shift in how the public views weight loss.

However, this class of drugs has also become increasingly costly for the U.S. healthcare system, according to a recent report out of IRIS, Real Chemistry’s obesity market intelligence platform.